Fangzhou Inc., a popular AI-empowered Internet healthcare solutions provider and Tencen Healthcare together introduced a robust ‘AI+Chronic Disease Management’ solution for smart understanding and capturing precision at the tech level. This is a crucial step and a sign of confidence in the history of deploying artificial intelligence across China’s healthcare market. The collaboration serves the best unified technology pipeline to industry partners, covering scenario verification and model training to embed it in the healthcare operation.
Both companies focus on effectively modernising chronic-disease management after sensing the need for precision and analysis in the care sector, due to the growing prevalence of this disease. This new era of high-efficiency and smart service delivery will accelerate in the global healthcare market.
This solution stands on Fangzhou’s excellent AI+H2H (Hospital to Home) ecosystem. It’s a deep architecture figure that equips an exclusive large model’s capability into the chronic disease procedure. Whereas, a popular cloud services provider, Tencent Cloud delivers a vast, potent long long-supported technological domains involving big data, artificial intelligence and cloud computing. This smart partnership will bring a comprehensive technological foundation to the tech health ground for the transition of AI-improved chronic disease management.
The Chairman, CEO and Founder of Fangzhou, Dr Xie Fangmin, said, “By merging our expert chronic disease management and healthcare with Tencent Healthcare’s industrial-level infrastructure, we are introducing a scalable, qualified AI potential to the global healthcare ecosystem. Alongside, we’re increasing the standard bar for the change and new phase of chronic disease management in China.”
This introduction of a new AI solution came from the seriousness and realisation of AI-growth momentum in Fangzhou’s operations. In October, the Company’s ‘medical report interpretation’ witnessed a robust acceptance in identifying a vast patient group’s need to precisely understand the critical lab results. The growing engagement stages and sessions’ volume mirrors emerging user confidence in bringing AI into the light.
In this, Fangzhou’s approach the compliance and safety was prioritized. To identify the barriers of AI adverse possibilities in sensitive clinical settings, the company executed multiple stages of protection involving rule-based supervision, medical-circumstances alignment checks and strengthening learning with assembled knowledge bases. Fangzhou has invested trust and confidence by installing its model in Tencent’s TI platform that elevates examination, deployment and one-stop training pipelines to allow consistent model refinement.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
